Mackay Sean 4

What Happened

• Sean Mackay, SVP & Chief Business Officer of Standard BioTools (LAB), received equity awards on March 20, 2026: 272,107 restricted stock units (RSUs) and 612,240 derivative awards (option-style), both reported as acquisitions at $0.00 (total reported cash paid $0).

Key Details

• Transaction date: 2026-03-20; Form 4 filed: 2026-04-08 (filed late relative to the typical 2-business-day Form 4 deadline).
• Transaction code: A (award/grant).
• Shares awarded: 272,107 RSUs + 612,240 derivative/option-style awards = 884,347 total award units.
• Price: $0.00 per share/unit (grant, not a purchase).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes/vesting: F1 — RSUs vest over four years: 1/16 vests on May 20, 2026, then equal quarterly installments thereafter; each RSU converts to one share at vesting. F2 — The derivative award (option) becomes exercisable as to 1/16 of the underlying shares on May 20, 2026, with the remainder vesting in equal quarterly installments, subject to continued service.

Context

• These are compensation/retention awards, not open-market purchases or sales; they do not represent an immediate cash investment or liquidation. The derivative award is a future exercisable right and does not indicate an immediate exercise or sale. The late filing is noted (may reflect administrative delay), but the grant itself is a routine executive compensation event rather than an immediate trading signal for retail investors.